Dr. Hani Osman, Consultant Haematologist, Tawam Hospital, United Arab Emirates, speaks about the CLL Management in Clinic and provides the following details:

• Details about the case report of relapsed CLL patient’s journey from his clinic.

• Discusses patient’s initial treatment with first generation BTK inhibitor ibrutinib and development of intolerable side effects.

Patient later being shifted to second generation BTK inhibitor based on NCCN recommendations.

 

 

Explore more videos

Translating Data Into Clinical Practice

Dr. Abdulkareem Algarni, KSA

Critical Evaluation of BTKis in CLL

Dr. George Follows, UK

Evolvement of CLL Management

Dr. Mahmoud Marashi, UAE